^
    Back
    Association details:
    Biomarker:MYC expression
    Cancer:Small Cell Lung Cancer
    Drug:barasertib-HQPA (AZD2811) (Aurora kinase B inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ESMO 2019
    Title:

    3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

    Published date:
    09/28/2019
    Excerpt:
    Comparing protein expression, we found that cMYC (Fold change, FC:2.5; P = 0.015) and Vimentin (FC:1.66; P = 0.022) were top biomarkers of sensitivity, while high E-cadherin (FC:1.94; P = 0.046) and BCL-2 (FC:1.86; P = 0.032) associated with resistance.
    DOI:
    10.1093/annonc/mdz264